BEMDANEPROCEL
UNII NET3NQ7GVS

Substance Identification & Data

This profile provides standardized clinical and technical data for Bemdaneprocel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NET3NQ7GVS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NET3NQ7GVS

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BEMDANEPROCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190471

National Cancer Institute reference terminology for clinical and research data.

INN ID

12185

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-152

Identifier assigned by the United States Adopted Names Council.

Substance Type

Bemdaneprocel

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bemdaneprocel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Bemdaneprocel

Common Names & Synonyms

BEMDANEPROCEL [USAN]

allogenic dopaminergic neural progenitor cells derived from the WA09 human embryonic stem cell (hESC) working cell bank (WCB). The cells are expanded and differentiated on plates coated with a basement membrane extract. Cells are initially grown in a xeno-free and feeder-free medium supplemented with a Rho-associated protein kinase (ROCK) inhibitor. The cells are then replated into polyornithine, laminin, and fibronectin coated flasks to undergo multiple maturation/differentiation steps in neurobasal media containing: bone morphogenetic protein (BMP) inhibitor, anaplastic lymphoma kinase (ALK) inhibitor, sonic hedgehog, glycogen synthase kinase (GSK) 3 inhibitor, brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), cAMP, transforming growth factor beta-3 (TGFB3), and a γ-secretase inhibitor. The major cell population consists of midbrain dopamine neuron progenitor cells indicated by the dopamine neuron precursor marker forkhead box protein A2 (FOXA2, >85%), the midbrain dopamine cell markers LIM homeobox transcription factor 1-alpha (LMX1A;<20.95 quantification cycle (Cq)) and pituitary homeobox 3 (PITX3;<28.23 Cq) and the dopaminergic cell marker tyrosine hydroxylase (TH; <24.70 Cq). The final substance also contains a minor cell population of forebrain cells (paired box protein (PAX6); <5%), but no detectable pluripotent stem cells indicated by the absence of the homeobox protein NANOG (<0.2%) and low levels of the octamer-binding transcription factor 4 (OCT4; >26.95 Cq)

bemdaneprocel [INN]

Technical Codes

BRT-DA01

MSK-DA01

External Clinical & Regulatory Resources

Previous UNIINER93KF8CN

Next UNIINET659B30S